Dr Nicolas Huber
Chief Executive Officer
Dr Huber completed his PhD in Space Science in reconfigurable hardware for space weather exploration on the International Space Station. After working in the aerospace sector he transitioned to the biomedical sciences, and over the past 8 years has been focused on medical device research and commercialization, where he developed and led a new portfolio of medical devices in radiation therapy for cancer treatment, building and leading a product development team and a new business line within an established multinational.
Dr Huber for the past few years has also been mentoring Healthcare startups through established accelerators (Wayra, RG, TechStars), specializing in business model development, market access and positioning
Dr Alex Betz
Dr Betz completed a PhD on the hypermutation of immunoglobulin genes at the MRC Laboratory of Molecular Biology, Cambridge UK. After 3.5 years working as a post-doc at the Howard Hughes Medical Institute, Johns Hopkins University, Baltimore USA, he was recruited back to the MRC Laboratory of Molecular Biology. His initial research interest was the regulation of lymphocyte migration by chemokines. In 2004 he published his group’s breakthrough discovery that regulatory T cells maintain maternal tolerance to the fetus. He retired from academic research in 2015 and now focuses on helping commercial projects.
Dr Edward Gibson
Dr Gibson holds a holds a degree in Chemistry from Bristol University, and a PhD in Biochemistry from Oxford University, where he also performed postdoctoral research. Since then, he has held a number of senior leadership roles with Bristol-Myers Squibb, focusing on commercialization and lifecycle management within the company’s oncology department, rising to becoming a member of the European oncology steering committee. He then went on to become Senior Director for New Product Strategy and EU commercialization with AVEO, as a member of the senior executive team. Since 2013, he has held the role of Global Pharma Key Opinion Leader for the Korean Health Industry Development Institute, and has devoted himself in the development of solutions to complex issues in healthcare access a CEO of an independent consultancy.
Mr Peter Klimt
Mr Klimt is an experienced entrepreneur with extensive practical expertise in international business including investment, and mergers and acquisitions.
He has professional qualifications in law and practised as a corporate lawyer. He is currently CEO of Welbeck Investment Management Limited.